A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Cutaneous Warts
Interventions
DRUG

AV2-SA2

AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.

DRUG

SA

Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.

Trial Locations (1)

2610

University of Antwerp, Antwerp

All Listed Sponsors
lead

Universiteit Antwerpen

OTHER

NCT05862441 - A Study to Assess the Efficacy of Omnivirol-Salicylic Acid Combination Therapy for Cutaneous Warts With Emphasis on Persistent Warts | Biotech Hunter | Biotech Hunter